No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized controlled trial

Category Primary study
JournalJOURNAL OF CLINICAL LIPIDOLOGY
Year 2023
BACKGROUND: Statins are the leading lipid -lowering drugs, reducing blood cholesterol by controlling its synthesis. Side effects are linked to the use of statins, in particular statin-associated muscle symptoms (SAMS). Some data suggest that vitamin D supplementation could reduce SAMS. OBJECTIVE: The purpose of this study was to evaluate the potential benefits of vitamin D supplementation in a randomized controlled trial. METHODS: Men ( n = 23) and women ( n = 15) (50.5 +/- 7.7 years [mean +/- SD]) in primary cardiovascular prevention, self -reporting or not SAMS, were recruited. Following 2 months of statin withdrawal, patients were randomized to supplementation (vitamin D or placebo). After 1 month of supplementation, statins were reintroduced. Before and 2 months after drug reintroduction, muscle damage (creatine kinase and myoglobin) was measured. Force (F), endurance (E) and power (P) of the leg extensors ( ExT ) and flexors ( fLE ) and handgrip strength (FHG) were also measured with isokinetic and handheld dynamometers, respectively. The Short Form 36 Health Survey (SF -36) questionnaire and a visual analog scale (VAS) were administrated to assess participants' self -reported health -related quality of life and SAMS intensity, respectively. Repeated -measures analysis was used to investigate the effects of time, supplementation, and their interaction, according to the presence of SAMS. RESULTS: Despite no change for objective measures, subjective measures worsened after reintroduction of statins, independent of supplementation (VAS, SF -36 mental component score, all p < 0.05). However, no interaction between time and supplementation according to the presence of SAMS was observed for any variables. CONCLUSIONS: Vitamin D supplementation does not appear to mitigate SAMS. (c) 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Epistemonikos ID: ea67e046077f53af4a09592446e15ad64e8ea074
First added on: Jan 05, 2024